The ChatGPT maker is folding Orchestra’s drug-program agents into Rosalind, its life sciences suite, betting AI can shave time off the decade-plus it takes to bring a medicine to patients.
DecryptOriginal link
Disclaimer: The market is risky, and investment needs to be cautious. This article does not constitute investment advice. Users should consider whether any opinions, views, or conclusions in this article are in line with their specific circumstances. Investment based on this is at their own risk.